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Introduction: The risk of thromboembolism in patients with atrial fibrillation becomes higher if they 
have comorbidities such as ischemic heart disease, hypertension, and diabetes.1 The risk for cardio-
embolic complications has been linked to a reduced ejection fraction (rEF) in several studies and has 
been well known for decades. An ejection fraction of 40–49% is neither normal/pre- served (pEF) nor 
reduced, and it is termed mid-range EF (mrEF). It is increasing in prevalence and is associated with 
older age, non-cardiac comorbidities and higher rates of AF. This category was separated in recent 
guidelines, although associated risks and the potential therapy remain poorly understood. We aimed 
to assess stroke/systemic embolism, major bleeding and mortality risks in our cohort of non-valvular 
AF patients based on the presence of mrEF in comparison to rEF and pEF. 
Patients and Methods: We studied 1000 consecutive patients who were admit- ted to our hospital due 
to non-valvular AF between 2013 and 2018. 
Results: Patients with mrEF presented with older age (P < 0.001) and a higher frequency of arterial 
hypertension (P = 0.001) in comparison to both pEF and rEF patients. In comparison to pEF, mrEF pa-
tients were more likely to have diabetes mellitus (P = 0.004), lower HDL-cholesterol (P < 0.001) and lower 
estimated glomerular filtration rate (P < 0.001), significantly higher CHA2DS2-VASC score (P < 0.001), 
significantly higher HAS-BLED score (P = 0.002) and had a higher likelihood of receiving anticoagulant 
therapy, mostly warfarin (P = 0.001). In addition, mrEF patients had a significantly higher risk of throm-
botic events (HR = 2.22; P = 0.015), death (HR = 1.71; P = 0.005) and composite endpoint of thrombosis, 
bleeding or death (HR = 1.65; P = 0.003) in comparison to pEF patients but did not significantly differ 
in comparison to rEF patients. There was no significant difference regarding major bleeding risk. As-
sociations with clinical outcomes remained statistically significant in multivariate models indepen-
dently of CHA2DS2-VASC. 
Conclusion: Our findings support defining AF patients with mrEF as a subgroup with distinct clini-
cal characteristics and increased risk for thrombotic events and death, irrespective of predetermined 
CHA2DS2-VASC risk. 
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